malignancies) including lymphoma and leukaemia.
We believe this aggressive IVL extravasated into the lymph nodes, liver, bladder, and adrenal parenchyma as a diffuse large B-cell
The primary endpoint was the correlation of CD 19 B-cell
count to new gadolinium-enhancing brain lesions (a proxy measure for disease activity).
The discovery could lead to the development of an early-warning test that identifies patients at high risk of developing B-cell
lymphomas, enabling proactive treatment to prevent tumours from growing.
According to the company's PIXUVRI's market access in Italy for multiply relapsed or refractory aggressive B-cell
NHL is based on the results of the EXTEND, or PIX301, pivotal randomized Phase 3 clinical trial.
neoplasms can involve lymph nodes, bone marrow, and/or extranodal or extramedullary sites.
Primary cutaneous diffuse large B-cell
lymphoma, leg type must be differentiated from anaplastic large-cell lymphoma and non-lymphoid tumors such as cutaneous metastases.
We describe a new case of marginal-zone B-cell
lymphoma of the bony palate in which these diagnostic challenges were encountered and overcome.
Three of the five responses were in patients with diffuse large B-cell
Comment: Rituxan is a monoclonal antibody directed at the CD20 antigen, present on the surface of normal and malignant B lymphocytes and expressed on more than 90% of B-cell
NHLs, but not on hematopoietic stem cells or normal plasma cells.
This tumor was positive for CD-30, partially positive for EMA but negative for B-cell
and T-cell markers (CD 20, CD 79a, CD2, CD3, CD4, CD43 and CD45RO).
ZEVALIN is approved in Europe for the treatment of adult patients with CD20+ follicular B-cell
non-Hodgkin's lymphoma (NHL) who are refractory to or have relapsed following RITUXAN (rituximab) therapy.
VIENNA -- Routine screening for evidence of infection by Borrelia burgdorferi, or hepatitis C virus, is warranted in patients with primary cutaneous B-cell
lymphoma, Antonio Cozzio, M.
No one knows what role the factors play in the disease, but Edwards contends that they set off a "vicious cycle" of B-cell
In transformed B-cell
lines from individuals affected with XLA, the expression level of Btk mRNA and protein, and consequently its kinase activity, was reduced or absent.